Top

Published in:

Open Access 01-12-2013 | Original investigation

Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk

Authors: Martí Juanola-Falgarona, Jordi Salas-Salvadó, Ramon Estruch, Maria P Portillo, Rosa Casas, Jonatan Miranda, Miguel A Martínez-González, Mònica Bulló

Published in: Cardiovascular Diabetology | Issue 1/2013

Abstract

Background

Vitamin K has been related to glucose metabolism, insulin sensitivity and diabetes. Because inflammation underlies all these metabolic conditions, it is plausible that the potential role of vitamin K in glucose metabolism occurs through the modulation of cytokines and related molecules. The purpose of the study was to assess the associations between dietary intake of vitamin K and peripheral adipokines and other metabolic risk markers related to insulin resistance and type 2 diabetes mellitus.

Methods

Cross-sectional and longitudinal assessments of these associations in 510 elderly participants recruited in the PREDIMED centers of Reus and Barcelona (Spain). We determined 1-year changes in dietary phylloquinone intake estimated by food frequency questionnaires, serum inflammatory cytokines and other metabolic risk markers.

Results

In the cross-sectional analysis at baseline no significant associations were found between dietary phylloquinone intake and the rest of metabolic risk markers evaluated, with exception of a negative association with plasminogen activator inhibitor-1. After 1-year of follow-up, subjects in the upper tertile of changes in dietary phylloquinone intake showed a greater reduction in ghrelin (−15.0%), glucose-dependent insulinotropic peptide (−12.9%), glucagon-like peptide-1 (−17.6%), IL-6 (−27.9%), leptin (−10.3%), TNF (−26.9%) and visfatin (−24.9%) plasma concentrations than those in the lowest tertile (all p<0.05).

Conclusion

These results show that dietary phylloquinone intake is associated with an improvement of cytokines and other markers related to insulin resistance and diabetes, thus extending the potential protection by dietary phylloquinone on chronic inflammatory diseases.

Trial registration

http://www.controlled-trials.com as ISRCTN35739639

Iwamoto J, Sato Y, Takeda T, Matsumoto H: Bone quality and vitamin K2 in type 2 diabetes: review of preclinical and clinical studies. Nutr Rev. 2011, 69 (3): 162-167. 10.1111/j.1753-4887.2011.00380.x.CrossRefPubMed

Shearer MJ: The roles of vitamins D and K in bone health and osteoporosis prevention. Proc Nutr Soc. 1997, 56 (3): 915-937. 10.1079/PNS19970099.CrossRefPubMed

Booth SL: Roles for vitamin K beyond coagulation. Annu Rev Nutr. 2009, 29: 89-110. 10.1146/annurev-nutr-080508-141217.CrossRefPubMed

Yoshida M, Booth SL, Meigs JB, Saltzman E, Jacques PF: Phylloquinone intake, insulin sensitivity, and glycemic status in men and women. Am J Clin Nutr. 2008, 88 (1): 210-215.PubMedCentralPubMed

Kumar R, Binkley N, Vella A: Effect of phylloquinone supplementation on glucose homeostasis in humans. Am J Clin Nutr. 2010, 92 (6): 1528-1532. 10.3945/ajcn.2010.30108.PubMedCentralCrossRefPubMed

Beulens JW, van Der ADL, Grobbee DE, Sluijs I, Spijkerman AM, van der Schouw YT: Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care. 2010, 33 (8): 1699-1705. 10.2337/dc09-2302.PubMedCentralCrossRefPubMed

Ibarrola-Jurado N, Salas-Salvado J, Martinez-Gonzalez MA, Bullo M: Dietary phylloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease. Am J Clin Nutr. 2012, 96 (5): 1113-1118. 10.3945/ajcn.111.033498.CrossRefPubMed

Ohsaki Y, Shirakawa H, Hiwatashi K, Furukawa Y, Mizutani T, Komai M: Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem. 2006, 70 (4): 926-932. 10.1271/bbb.70.926.CrossRefPubMed

Shea MK, Booth SL, Massaro JM, Jacques PF, D’Agostino RBS, Dawson-Hughes B, Ordovas JM, O’Donnell CJ, Kathiresan S, Keaney JF, Vasan RS, Benjamin EJ: Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol. 2008, 167 (3): 313-320.PubMedCentralCrossRefPubMed

10.

Shea MK, Dallal GE, Dawson-Hughes B, Ordovas JM, O’Donnell CJ, Gundberg CM, Peterson JW, Booth SL: Vitamin K, circulating cytokines, and bone mineral density in older men and women. Am J Clin Nutr. 2008, 88 (2): 356-363.PubMedCentralPubMed

11.

Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, Fiol M, Gomez-Gracia E, Lopez-Sabater MC, Vinyoles E, Aros F, Conde M, Lahoz C, Lapetra J, Saez G, Ros E, PREDIMED Study Investigators: Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006, 145 (1): 1-11.CrossRefPubMed

12.

Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ros E, Covas MI, Fiol M, Warnberg J, Aros F, Ruiz-Gutierrez V, Lamuela-Raventos RM, Lapetra J, Munoz MA, Martinez JA, Saez G, Serra-Majem L, Pinto X, Mitjavila MT, Tur JA, Portillo MD, Estruch R, for the PREDIMED Study Investigators: Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol. 2012, 41 (2): 377-385. 10.1093/ije/dyq250.CrossRefPubMed

13.

Fernandez-Ballart JD, Pinol JL, Zazpe I, Corella D, Carrasco P, Toledo E, Perez-Bauer M, Martinez-Gonzalez MA, Salas-Salvado J, Martin-Moreno JM: Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr. 2010, 103 (12): 1808-1816. 10.1017/S0007114509993837.CrossRefPubMed

14.

Schroder H, Fito M, Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Lamuela-Raventos R, Ros E, Salaverria I, Fiol M, Lapetra J, Vinyoles E, Gomez-Gracia E, Lahoz C, Serra-Majem L, Pinto X, Ruiz-Gutierrez V, Covas MI: A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011, 141 (6): 1140-1145. 10.3945/jn.110.135566.CrossRefPubMed

15.

Moreiras O, Carbajal A, Cabrera L, Cuadrado C: Tablas de composición de los alimentos. (Food Composition Tables). 2005, Madrid: Pirámide, 9th

16.

Mataix Verdú J: Tabla de composicion de alimentos [Food Composition Tables]. 2003, Granada (Spain): Universidad de Granada, 4th

17.

Pan Y, Jackson RT: Dietary phylloquinone intakes and metabolic syndrome in US young adults. J Am Coll Nutr. 2009, 28 (4): 369-379.CrossRefPubMed

18.

Bullo M, Moreno-Navarrete JM, Fernandez-Real JM, Salas-Salvado J: Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and beta cell function in elderly men at high cardiovascular risk. Am J Clin Nutr. 2012, 95 (1): 249-255. 10.3945/ajcn.111.016642.CrossRefPubMed

19.

Fernandez-Fernandez L, Bellido-Martin L, Garcia de Frutos P: Growth arrest-specific gene 6 (GAS6). An outline of its role in haemostasis and inflammation. Thromb Haemost. 2008, 100 (4): 604-610.PubMed

20.

Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi Y, Yasutake T, Sakamaki T, Pestell RG, Yamamoto K: Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin Cancer Res. 2007, 13 (7): 2236-2245. 10.1158/1078-0432.CCR-06-2308.CrossRefPubMed

21.

Tanaka S, Nishiumi S, Nishida M, Mizushina Y, Kobayashi K, Masuda A, Fujita T, Morita Y, Mizuno S, Kutsumi H, Azuma T, Yoshida M: Vitamin K3 attenuates lipopolysaccharide-induced acute lung injury through inhibition of nuclear factor-kappaB activation. Clin Exp Immunol. 2010, 160 (2): 283-292.PubMedCentralCrossRefPubMed

22.

Ohsaki Y, Shirakawa H, Miura A, Giriwono PE, Sato S, Ohashi A, Iribe M, Goto T, Komai M: Vitamin K suppresses the lipopolysaccharide-induced expression of inflammatory cytokines in cultured macrophage-like cells via the inhibition of the activation of nuclear factor kappaB through the repression of IKKalpha/beta phosphorylation. J Nutr Biochem. 2010, 21 (11): 1120-1126. 10.1016/j.jnutbio.2009.09.011.CrossRefPubMed

23.

Li J, Lin JC, Wang H, Peterson JW, Furie BC, Furie B, Booth SL, Volpe JJ, Rosenberg PA: Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci. 2003, 23 (13): 5816-5826.PubMed

24.

Reddi K, Henderson B, Meghji S, Wilson M, Poole S, Hopper C, Harris M, Hodges SJ: Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. Cytokine. 1995, 7 (3): 287-290. 10.1006/cyto.1995.0034.CrossRefPubMed

25.

Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest. 2006, 116 (7): 1793-1801. 10.1172/JCI29069.PubMedCentralCrossRefPubMed

26.

Goldberg RB: Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009, 94 (9): 3171-3182. 10.1210/jc.2008-2534.CrossRefPubMed

27.

Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun I, Kim KW, Kwon YG, Yoo MA, Bae MK: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008, 1783 (5): 886-895. 10.1016/j.bbamcr.2008.01.004.CrossRefPubMed

28.

Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, Chou MM, Sheu WH: Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. Int J Obes (Lond). 2009, 33 (4): 465-472. 10.1038/ijo.2009.24.CrossRef

29.

Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, Tschop MH, D’Alessio D: Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010, 59 (9): 2145-2151. 10.2337/db10-0504.PubMedCentralCrossRefPubMed

30.

Schofl C, Horn R, Schill T, Schlosser HW, Muller MJ, Brabant G: Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002, 87 (10): 4607-4610. 10.1210/jc.2002-020505.CrossRefPubMed

31.

Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O: Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003, 52 (10): 2546-2553. 10.2337/diabetes.52.10.2546.CrossRefPubMed

32.

McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE: Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. J Clin Endocrinol Metab. 2004, 89 (4): 1630-1635. 10.1210/jc.2003-031572.CrossRefPubMed

33.

Ostergard T, Hansen TK, Nyholm B, Gravholt CH, Djurhuus CB, Hosoda H, Kangawa K, Schmitz O: Circulating ghrelin concentrations are reduced in healthy offspring of Type 2 diabetic subjects, and are increased in women independent of a family history of Type 2 diabetes. Diabetologia. 2003, 46 (1): 134-136.PubMed

34.

Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, Eppler E, Bouzakri K, Wueest S, Muller YD, Hansen AM, Reinecke M, Konrad D, Gassmann M, Reimann F, Halban PA, Gromada J, Drucker DJ, Gribble FM, Ehses JA, Donath MY: Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011, 17 (11): 1481-1489. 10.1038/nm.2513.PubMedCentralCrossRefPubMed

35.

Nie Y, Ma RC, Chan JC, Xu H, Xu G: Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J. 2012, 26 (6): 2383-2393. 10.1096/fj.11-196782.CrossRefPubMed

36.

Omar B, Banke E, Guiguis E, Kesson L, Manganiello V, Lyssenko V, Groop L, Gomez MF, Degerman E: Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes - A role for the transcription factor NFAT and phosphodiesterase 3B. Biochem Biophys Res Commun. 2012, 425 (4): 812-819. 10.1016/j.bbrc.2012.07.157.PubMedCentralCrossRefPubMed

Title: Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk
Authors: Martí Juanola-Falgarona
Jordi Salas-Salvadó
Ramon Estruch
Maria P Portillo
Rosa Casas
Jonatan Miranda
Miguel A Martínez-González
Mònica Bulló
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-12-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk

Abstract

Background

Methods

Results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2013

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes – a cross-sectional study

Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients

Prognostic value of coronary flow reserve assessed by transthoracic Doppler echocardiography on long-term outcome in asymptomatic patients with type 2 diabetes without overt coronary artery disease

Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normoglycemic individuals

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes

Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page